検索画面
細胞材料開発室サイト

戻る 戻る
細胞番号 : 細胞名
RCB1196 : TGBC24TKB  update : 2023/01/25
細胞特性(Comment:英)Japanese gallbladder carcinoma established from metastated ascite. Application consideration
細胞特性(日)日本人胆嚢癌。腹水より採取。培養開始にあたっての注意
細胞特性(寄託者記述:英)
細胞特性(寄託者記述:日)
使用条件(英)There is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC.
使用条件(日)基礎的研究につきましては、使用制限はありません。商業利用や特許取得を目的とする場合は、事前に必ず理研細胞バンクに連絡をすること。
備考(英)
備考(日)
提供申込書類(英) Order Form(C-0005.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)  
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
提供申込書類(日) 依頼書C-0001.pdf   同意書(非営利学術目的)C-0003.pdf   同意書(営利目的)C-0003p.pdf  
提供同意書は、使用機関の種類や目的に応じて、非営利学術目的 (C-XXXX) と営利目的 (C-XXXXp) の2種類があります。該当する提供同意書をご使用ください(詳細)。特許等の取得及び商業利用等は事前に必ず cellbank.brc@riken.jp までご連絡ください。
提供手数料 手数料とお支払いについてはこちらをご覧ください。
細胞基本情報 寄託者 Todoroki, T. & Ohno, T.
樹立者 Saijo, Kaoru & Kim, Boms
寄託日 1995
別名 YoMi
動物種 human < Mammals
属名 Homo
種名 sapiens
人種 Japanese
性別 Female
採取組織 gallbladder, ascites meta
病名 gallbladder carcinoma
転移 Yes
転移巣 ascites
細胞分類 cancer
初代培養日 1995
細胞寿命 infinite
細胞形態 epithelial-like
Cellosaurus(Expasy) CVCL_1770
細胞培養・検査情報
寄託時情報
ロット情報
培地・試薬情報 培地・試薬一覧はこちらをご覧ください。
培養形態 Adherent cells
培地 DMEM (low glucose) + 10% FBS
抗生物質 Free
継代方法 0.25% Trypsin
継代密度 1 : 8 split
継代・培地交換頻度 Subculture : once/1-2 weeks, Medium Renewal : 2 times/week
培養最適温度 37 ℃
二酸化炭素濃度 5 %
凍結培地 Medium + 10% DMSO
凍結方法 Slow freezing
マイコプラズマ (-)
ウィルス(HBV) (-)
ウィルス(HCV) (-)
アイソザイム検査 LD, NP
染色体検査 58-64(50) : 58(5),59(2),60(7),61(11),62(22),63(2)/
個体識別検査 OK
画像情報
寄託時情報
ロット情報
文献情報 Reference(英) 0件
Reference(日) 0件
利用者成果(英) 25件
利用者成果(日) 0件

トップへページトップへ
Reference(英)

トップへページトップへ
Reference(日)

トップへページトップへ
利用者成果(英)
15892  Khorsandi SE, Dokal AD, Rajeeve V, Britton DJ, Illingworth MS, Heaton N, Cutillas PR.  Computational Analysis of Cholangiocarcinoma Phosphoproteomes Identifies Patient-Specific Drug Targets.  Cancer Res  2021  81(22):5765-5776  PubMed ID: 34551960   DOI: 10.1158/0008-5472.CAN-21-0955
13185  Pandey A, Stawiski EW, Durinck S, Gowda H, Goldstein LD, Barbhuiya MA, Schröder MS, Sreenivasamurthy SK, Kim SW, Phalke S, Suryamohan K, Lee K, Chakraborty P, Kode V, Shi X, Chatterjee A, Datta K, Khan AA, Subbannayya T, Wang J, Chaudhuri S, Gupta S, Shrivastav BR, Jaiswal BS, Poojary SS, Bhunia S, Garcia P, Bizama C, Rosa L, Kwon W, Kim H, Han Y, Yadav TD, Ramprasad VL, Chaudhuri A, Modrusan Z, Roa JC, Tiwari PK, Jang JY, Seshagiri S.  Integrated genomic analysis reveals mutated ELF3 as a potential gallbladder cancer vaccine candidate.  Nat Commun  2020    PubMed ID: 32839463   DOI: 10.1038/s41467-020-17880-4
13336  Pan YR, Wu CE, Yeh CN.  ATM Inhibitor Suppresses Gemcitabine-Resistant BTC Growth in a Polymerase θ Deficiency-Dependent Manner.  Biomolecules  2020    PubMed ID: 33182492   DOI: 10.3390/biom10111529
13778  Yamashita T, Kato K, Fujihara S, Iwama H, Morishita A, Yamana H, Kobayashi K, Kamada H, Chiyo T, Kobara H, Tsutsui K, Okano K, Suzuki Y, Masaki T.  Anti-diabetic drug metformin inhibits cell proliferation and tumor growth in gallbladder cancer via G0/G1 cell cycle arrest  Anticancer Drugs  2020  31(3):231-240  PubMed ID: 31815765   DOI: 10.1097/CAD.0000000000000870
20122  Hendaoui I, Lahmar A, Campo L, Mebarki S, Bichet S, Hess D, Degen M, Kchir N, Charrada-Ben Farhat L, Hefaiedh R, Ruiz C, Terracciano LM, Tucker RP, Hendaoui L, Chiquet-Ehrismann R.  Tenascin-W Is a Novel Stromal Marker in Biliary Tract Cancers.  Front Immunol  2020  11:630139  PubMed ID: 33692777   DOI: 10.3389/fimmu.2020.630139
11395  Subbannayya T, Leal-Rojas P, Zhavoronkov A, Ozerov IV, Korzinkin M, Babu N, Radhakrishnan A, Chavan S, Raja R, Pinto SM, Patil AH, Barbhuiya MA, Kumar P, Guerrero-Preston R, Navani S, Tiwari PK, Kumar RV, Prasad TSK, Roa JC, Pandey A, Sidransky D, Gowda H, Izumchenko E, Chatterjee A.  PIM1 kinase promotes gallbladder cancer cell proliferation via inhibition of proline-rich Akt substrate of 40 kDa (PRAS40).  J Cell Commun Signal  2019    PubMed ID: 30666556   DOI: 10.1007/s12079-018-00503-5
11422  Hori R, Yamaguchi K, Sato H, Watanabe M, Tsutsumi K, Iwamoto S, Abe M, Onodera H, Nakamura S, Nakai R.  The discovery and characterization of K-563, a novel inhibitor of the Keap1/Nrf2 pathway produced by Streptomyces sp.  Cancer Med  2019    PubMed ID: 30735010   DOI: 10.1002/cam4.1949
3726  Kirti Gondkar, Krishna Patel, Geeta V. Patil Okaly, Bipin Nair, Akhilesh Pandey, Harsha Gowda and Prashant Kumar  Dickkopf Homolog 3 (DKK3) Acts as a Potential Tumor Suppressor in Gallbladder Cancer  Front Oncol  2019  9:1121  PubMed ID: 31737564   DOI: 10.3389/fonc.2019.01121
3737  Sakamoto Y, Yamagishi S, Okusaka T, Ojima H.  Synergistic and Pharmacotherapeutic Effects of Gemcitabine and Cisplatin Combined Administration on Biliary Tract Cancer Cell Lines.  Cells  2019  8(9):1026  PubMed ID: 31484399   DOI: 10.3390/cells8091026
3738  Yamashita-Kashima Y, Yoshimura Y, Fujimura T, Shu S, Yanagisawa M, Yorozu K, Furugaki K, Higuchi R, Shoda J, Harada N.  Molecular targeting of HER2-overexpressing biliary tract cancer cells with trastuzumab emtansine, an antibody-cytotoxic drug conjugate.  Cancer Chemother Pharmacol.  2019  83(4):659-671  PubMed ID: 30659304   DOI: 10.1007/s00280-019-03768-8
10759  Sakamoto Y, Yamagishi S, Tanizawa Y, Tajimi M, Okusaka T, Ojima H.  PI3K-mTOR pathway identified as a potential therapeutic target in biliary tract cancer using a newly established patient-derived cell panel assay.  Jpn. J. Clin. Oncol.  2018  48:396-399  PubMed ID: 29474549   DOI: 10.1093/jjco/hyy011
14913  Lin G, Lin KJ, Wang F, Chen TC, Yen TC, Yeh TS.  Synergistic antiproliferative effects of an mTOR inhibitor (rad001) plus gemcitabine on cholangiocarcinoma by decreasing choline kinase activity  Dis Model Mech  2018  11(8):dmm03305  PubMed ID: 29666220   DOI: 10.1242/dmm.033050
10170  Weber H, Valbuena JR, Barbhuiya MA, Stein S, Kunkel H, García P, Bizama C, Riquelme I, Espinoza JA, Kurtz SE, Tyner JW, Calderon JF, Corvalán AH, Grez M, Pandey A, Leal-Rojas P, Roa JC.  Small molecule inhibitor screening identifified HSP90 inhibitor 17-AAG as potential therapeutic agent for gallbladder cancer.  Oncotarget  2017  8:26169-26184  PubMed ID: 28412732   DOI: 10.18632/oncotarget.15410
10222  Yang L, Huang S, Ma H, Wu X, Feng F.  MicroRNA-125b predicts clinical outcome and suppressed tumor proliferation and migration in human gallbladder cancer.  Tumour Biol.  2017  39:1010428317692249  PubMed ID: 28347246   DOI: 10.1177/1010428317692249
9533  Tadokoro T, Morishita A, Fujihara S, Iwama H, Niki T, Fujita K, Akashi E, Mimura S, Oura K, Sakamoto T, Nomura T, Tani J, Miyoshi H, Yoneyama H, Himoto T, Hirashima M, Masaki T.  Galectin-9: An anticancer molecule for gallbladder carcinoma.  Int. J. Oncol.  2016  48:1165-74  PubMed ID: 26797414   DOI: 10.3892/ijo.2016.3347
3729  Subbannayya T et al  Macrophage migration inhibitory factor - a therapeutic target in gallbladder cancer.  BMC Cancer  2015  15:843  PubMed ID: 26530123   DOI: 10.1186/s12885-015-1855-z
3736  Shirota T, Ojima H, Hiraoka N, Shimada K, Rokutan H, Arai Y, Kanai Y, Miyagawa S, Shibata T.  Heat Shock Protein 90 Is a Potential Therapeutic Target in Cholangiocarcinoma.  Mol Cancer Ther.  2015  14(9):1985-93  PubMed ID: 26141945   DOI: 10.1158/1535-7163.MCT-15-0069
13739  Letelier P, García P, Leal P, Álvarez H, Ili C, López J, Castillo J, Brebi P, Roa JC.  miR-1 and miR-145 act as tumor suppressor microRNAs in gallbladder cancer  Int J Clin Exp Pathol  2014  7(5):1849-67  PubMed ID: 24966896  
3715  Idrees AS, Sugie T, Inoue C, Murata-Hirai K, Okamura H, Morita CT, Minato N, Toi M, Tanaka Y.  Comparison of γδ T cell responses and farnesyl diphosphate synthase inhibition in tumor cells pretreated with zoledronic acid.  Cancer Sci  2013  104(5):536-42  PubMed ID: 23387443   DOI: 10.1111/cas.12124
7767  Miyamoto M, Ojima H, Iwasaki M, Shimizu H, Kokubu A, Hiraoka N, Kosuge T, Yoshikawa D, Kono T, Furukawa H, Shibata T.  Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma.  Br. J. Cancer  2011  105:131-8  PubMed ID: 21673683   DOI: 10.1038/bjc.2011.199
7862  Sato J, Kimura T, Saito T, Anazawa T, Kenjo A, Sato Y, Tsuchiya T, Gotoh M.  Gene expression analysis for predicting gemcitabine resistance in human cholangiocarcinoma.  J Hepatobiliary Pancreat Sci  2011  18:700-11  PubMed ID: 21451941   DOI: 10.1007/s00534-011-0376-7
13667  Ojima H, Yoshikawa D, Ino Y, Shimizu H, Miyamoto M, Kokubu A, Hiraoka N, Morofuji N, Kondo T, Onaya H, Okusaka T, Shimada K, Sakamoto Y, Esaki M, Nara S, Kosuge T, Hirohashi S, Kanai Y, Shibata T.  Establishment of six new human biliary tract carcinoma cell lines and identification of MAGEH1 as a candidate biomarker for predicting the efficacy of gemcitabine treatment  Cancer Sci  2010  101(4):882-8  PubMed ID: 20088962   DOI: 10.1111/j.1349-7006.2009.01462.x
3719  van Haaften G et al  Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer.  Nat Genet  2009  41(5):521-3  PubMed ID: 19330029   DOI: 10.1038/ng.349
6410  Danjoh I, Sone H, Noda N, Iimura E, Nagayoshi M, Saijo K, Hiroyama T, Nakamura Y.  Is parainfluenza virus a threatening virus for human cancer cell lines?  Hum Cell  2009  22(3):81-4  PubMed ID: 19624309   DOI: 10.1111/j.1749-0774.2009.00071.x
3717  Wada M, Yazumi S, Takaishi S, Hasegawa K, Sawada M, Tanaka H, Ida H, Sakakura C, Ito K, Ito Y, Chiba T.  Frequent loss of RUNX3 gene expression in human bile duct and pancreatic cancer cell lines.  Oncogene  2004  23(13):2401-7  PubMed ID: 14743205   DOI: 10.1038/sj.onc.1207395

トップへページトップへ
利用者成果(日)



戻る 戻る 理研トップページへ